Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company's breakthrough vaccine technology, oligoDOM, and how it's driving the development of new influenza and SARS-CoV-2 vacc
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
